Trius Therapeutics is a technology company.
Trius Therapeutics has raised $20.0M across 1 funding round.
Trius Therapeutics has raised $20.0M in total across 1 funding round.
Trius Therapeutics was a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative antibiotics for serious bacterial infections, particularly Gram-positive pathogens like methicillin-resistant *Staphylococcus aureus* (MRSA).[1][3][5] Its lead product, tedizolid phosphate (formerly TR-701), was an oral and IV oxazolidinone antibiotic that completed Phase 3 trials for acute bacterial skin and skin structure infections (ABSSSI) and pneumonia, receiving FDA approval in June 2014.[1][3] The company served patients with life-threatening infections, addressing the critical problem of antibiotic resistance by offering once-daily dosing with improved efficacy and safety over existing treatments like linezolid.[1][3]
Trius demonstrated strong growth momentum through clinical successes, partnerships (e.g., Bayer's $94 million deal for Asian rights in 2011), and a $3 million U.S. government contract, culminating in its $1.6 billion acquisition by Cubist Pharmaceuticals in July 2013 (later part of Merck).[1][3] Post-acquisition, tedizolid was commercialized under Cubist/Merck, with Trius operating as a subsidiary.[1]
Founded in 2004 in San Diego, California (with some records noting Massachusetts ties), Trius Therapeutics emerged from the need for novel antibiotics amid rising MRSA and Gram-positive infection threats.[1][2][3] Key founders included CFO John Schmid and Chief Scientific Officer John Finn, with leadership from CEO Jeffrey Stein, Chief Medical Officer Philippe Prokocimer, and others like Chief Commercial Officer Craig Thompson.[3] The idea stemmed from targeting underexplored bacterial enzymes like GyrB/ParE (preclinical fluoroquinolone-like inhibitors) and advancing tedizolid, building on oxazolidinone chemistry.[1][3]
Early traction included Phase 3 completion of tedizolid (ESTABLISH-1 trial success), a 2011 Lawrence Livermore contract, and Bayer licensing, propelling the company to IPO (NASDAQ: TSRX) and rapid scaling to 83 employees before acquisition.[3]
Trius rode the early 2010s wave of antimicrobial resistance (AMR) crisis, where superbugs like MRSA strained global healthcare amid pipeline droughts in antibiotics.[1][3][5] Timing was ideal post-2000s resistance surges, with U.S. government incentives (e.g., contracts) and FDA priorities favoring rapid approvals for unmet needs.[3] Market forces included declining Big Pharma antibiotic investment due to low margins, creating space for agile biotechs like Trius to innovate and license assets.[3] It influenced the ecosystem by validating oxazolidinones, boosting investor interest in anti-infectives, and contributing tedizolid to Merck's portfolio, aiding sustained commercialization amid ongoing AMR threats.[1][3]
Trius exemplified biotech success in high-need antibiotics, transforming from startup to $1.6B exit and FDA-approved drug. Post-acquisition, tedizolid remains active under Merck (via Cubist), with potential in expanding indications like pneumonia.[1][3] Future trends like escalating AMR (WHO priority) and new incentives (e.g., PASTEUR Act) could revive similar models, evolving Trius's legacy through Merck's global reach and pipeline integration.[1] Its story underscores how targeted innovation captures value in underserved biopharma niches.
Trius Therapeutics has raised $20.0M in total across 1 funding round.
Trius Therapeutics's investors include HealthQuest Capital.
Trius Therapeutics has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in February 2007.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2007 | $20.0M Series A | HealthQuest Capital |